financetom
Business
financetom
/
Business
/
Marwest Apartment REIT Q1 Profit Falls, Revenue Unchanged; Provides Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marwest Apartment REIT Q1 Profit Falls, Revenue Unchanged; Provides Outlook
May 17, 2024 4:35 AM

07:24 AM EDT, 05/17/2024 (MT Newswires) -- Marwest Apartment Real Estate Investment Trust (MAR-UN.V) overnight Thursday reported lower earnings for the first quarter while revenue remained unchanged.

The company reported first-quarter net income and comprehensive income of $618,024, down from $3.2 million a year earlier.

Revenue from investment properties for the quarter ended March 31 was $2.5 million, the same as the equivalent quarter of the previous year. Adjusted funds from operations for Q1 were $514,376, or $0.0264 per unit, up from $321,999, or $0.0165.

The same property net operating income increased by 14.51% in Q1, as compared with the year-ago quarter. The average occupancy rate in Q1 was 99.01% versus 98.30% a year earlier.

The same property net operating income in Q1 was $1.7 million, up from $1.4 million a year ago. The REIT reported net asset value per unit of $1.93 at March 31, up from $1.90 at Dec. 31, 2023.

Looking ahead, the REIT intends to grow the portfolio and unitholder value by increasing rental rates where the market allows, future acquisition opportunities that will increase the overall size and performance of the REIT, as well as maintaining a manageable debt structure.

"Q1 operations provided the REIT with a 14.51% increase in Same Property NOI1 compared to Q1 2023," William Martens, chief executive officer and trustee, said. "Continued stable occupancy levels due to the current rental market in Winnipeg, has allowed management to increase rental rates across the portfolio. Management expects similar demand and low vacancy rates to continue throughout 2024."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck Halts Phase 3 Trial of Lung Cancer Combination Therapy
Merck Halts Phase 3 Trial of Lung Cancer Combination Therapy
Aug 8, 2024
07:23 AM EDT, 08/08/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that it halted the phase 3 trial of its experimental combination therapy to treat patients with extensive-stage small cell lung cancer based on the recommendation of an independent data monitoring committee. The company said the trial, which tested a fixed-dose combination of vibostolimab and its blockbuster cancer...
US Foods' Fiscal Q2 Adjusted Earnings, Net Sales Rise; Fiscal 2024 Guidance Maintained
US Foods' Fiscal Q2 Adjusted Earnings, Net Sales Rise; Fiscal 2024 Guidance Maintained
Aug 8, 2024
07:22 AM EDT, 08/08/2024 (MT Newswires) -- US Foods Holding ( USFD ) reported fiscal Q2 adjusted earnings Thursday of $0.93 per diluted share, up from $0.79 a year earlier. Analysts polled by Capital IQ expected $0.93. Net sales for the quarter ended June 29 were $9.71 billion, compared with $9.01 billion a year earlier. Analysts surveyed by Capital IQ...
ATS Q1 Adjusted Earnings, Revenue Fall
ATS Q1 Adjusted Earnings, Revenue Fall
Aug 8, 2024
07:22 AM EDT, 08/08/2024 (MT Newswires) -- ATS (ATS.TO) reported Thursday lower adjusted earnings and revenues for the first quarter of its fiscal 2025. The automation solutions provider booked adjusted earnings from operations of $86.2 million, or $0.50 per share, dropping from $102.1 million, or $0.69 per share. Revenue fell 7.9% to $694.3 million while adjusted EBITDA sank 11% to...
Nuvalent's Q2 Net Loss Widens
Nuvalent's Q2 Net Loss Widens
Aug 8, 2024
07:22 AM EDT, 08/08/2024 (MT Newswires) -- Nuvalent ( NUVL ) reported a Q2 net loss Thursday of $0.88 per diluted share, widening from a loss of $0.51 a year earlier. Analysts polled by Capital IQ expected a loss of $0.76. The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended June 30. Nuvalent ( NUVL )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved